How much did Novartis’s Entresto sales fall in Q3 2026?
Novartis reported on October 27, 2026 that Entresto generated US$1.165 billion in Q3 2026 sales, down 38% at constant currency, according to Drugnews’s November 3, 2026 analysis. The sacubitril/valsartan brand’s first-nine-month sales were US$3.651 billion, versus US$6.495 billion a year earlier, following U.S. generic entry.
| Measure | Reported result | Basis |
|---|---|---|
| Q3 2026 sales | US$1.165 billion | Worldwide product sales |
| Q3 year-over-year decline | 38% | Constant currency |
| First nine months of 2026 | US$3.651 billion | Cumulative sales |
| Prior-year first nine months | US$6.495 billion | Matching cumulative period |
The quarterly growth rate and the nine-month sales totals cover different periods.